fluoxetine has been researched along with Alloxan Diabetes in 22 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The study was designed to find out the effect of thymoquinone (TQ) alone and combination of TQ + fluoxetine in depression of type-2 diabetic rats." | 7.91 | Thymoquinone and fluoxetine alleviate depression via attenuating oxidative damage and inflammatory markers in type-2 diabetic rats. ( Alam, MF; Anwer, T; Khan, G; Masmali, AUM; Qumayri, HM; Safhi, MM; Siddiqui, R, 2019) |
| " Several experimental groups were tested: (a) animals that were subjected to long-term (42-day) alloxan-hyperglycemia and protected with insulin, (b) healthy animals that received a low dose of insulin that does not produce changes in glycemia, and (c) animals that received long-term treatment with fluoxetine." | 7.91 | Responsivity of lateral septum-mPFC connections in alloxan-induced hyperglycemia. ( Contreras, CM; Gutiérrez-García, AG; Moreno-Cortés, ML, 2019) |
| " Therefore, the present study was aimed at investigating the effect of ondansetron, a selective 5HT3 receptor antagonist in attenuating depression and anxiety-like behavior comorbid with diabetes." | 7.80 | Ondansetron, a 5HT3 receptor antagonist reverses depression and anxiety-like behavior in streptozotocin-induced diabetic mice: possible implication of serotonergic system. ( Gupta, D; Kurhe, Y; Radhakrishnan, M, 2014) |
| "The study was designed to find out the effect of thymoquinone (TQ) alone and combination of TQ + fluoxetine in depression of type-2 diabetic rats." | 3.91 | Thymoquinone and fluoxetine alleviate depression via attenuating oxidative damage and inflammatory markers in type-2 diabetic rats. ( Alam, MF; Anwer, T; Khan, G; Masmali, AUM; Qumayri, HM; Safhi, MM; Siddiqui, R, 2019) |
| " Several experimental groups were tested: (a) animals that were subjected to long-term (42-day) alloxan-hyperglycemia and protected with insulin, (b) healthy animals that received a low dose of insulin that does not produce changes in glycemia, and (c) animals that received long-term treatment with fluoxetine." | 3.91 | Responsivity of lateral septum-mPFC connections in alloxan-induced hyperglycemia. ( Contreras, CM; Gutiérrez-García, AG; Moreno-Cortés, ML, 2019) |
| " Therefore, the present study was aimed at investigating the effect of ondansetron, a selective 5HT3 receptor antagonist in attenuating depression and anxiety-like behavior comorbid with diabetes." | 3.80 | Ondansetron, a 5HT3 receptor antagonist reverses depression and anxiety-like behavior in streptozotocin-induced diabetic mice: possible implication of serotonergic system. ( Gupta, D; Kurhe, Y; Radhakrishnan, M, 2014) |
| "Fluoxetine treatment significantly reduced the BW gain, hyperglycaemia, creatinine, and BUN in diabetic rats." | 1.72 | Oral fluoxetine treatment changes serotonergic sympatho-regulation in experimental type 1 diabetes. ( Alarcón-Torrecillas, C; Fernández-González, JF; García-Domingo, M; García-Pedraza, JÁ; López, C; Martín, ML; Morán, A; Rodríguez-Barbero, A, 2022) |
| "Fluoxetine and melatonin treatments decreased TBARS in both cortices." | 1.46 | The antidepressant effect of melatonin and fluoxetine in diabetic rats is associated with a reduction of the oxidative stress in the prefrontal and hippocampal cortices. ( Boudah, A; Jasmin, L; Rebai, R, 2017) |
| "Fluoxetine treatment, although having no effect in controls, corrected this parameter in diabetic mice." | 1.33 | Reduced hippocampal neurogenesis and number of hilar neurones in streptozotocin-induced diabetic mice: reversion by antidepressant treatment. ( Beauquis, J; De Nicola, A; Homo-Delarche, F; Roig, P; Saravia, F, 2006) |
| "Depression is highly prevalent in diabetics and is associated with poor glucose regulation and increased risk of diabetic complications." | 1.32 | Antidepressant activity of quercetin, a bioflavonoid, in streptozotocin-induced diabetic mice. ( Anjaneyulu, M; Chopra, K; Kaur, I, 2003) |
| "Diabetic mice exhibited significant hyperalgesia compared with control mice." | 1.32 | Fluoxetine attenuates thermal hyperalgesia through 5-HT1/2 receptors in streptozotocin-induced diabetic mice. ( Anjaneyulu, M; Chopra, K, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.55) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (27.27) | 29.6817 |
| 2010's | 13 (59.09) | 24.3611 |
| 2020's | 2 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| García-Pedraza, JÁ | 1 |
| Fernández-González, JF | 1 |
| López, C | 1 |
| Martín, ML | 1 |
| Alarcón-Torrecillas, C | 1 |
| Rodríguez-Barbero, A | 1 |
| Morán, A | 1 |
| García-Domingo, M | 1 |
| Yuan, P | 1 |
| Zhang, J | 1 |
| Li, L | 1 |
| Song, Z | 1 |
| Yang, H | 1 |
| Cao, Q | 1 |
| Xiong, X | 1 |
| Zhao, P | 1 |
| Shen, D | 1 |
| Zhang, Y | 1 |
| Zhang, N | 1 |
| Rebai, R | 1 |
| Jasmin, L | 1 |
| Boudah, A | 1 |
| Safhi, MM | 1 |
| Qumayri, HM | 1 |
| Masmali, AUM | 1 |
| Siddiqui, R | 1 |
| Alam, MF | 1 |
| Khan, G | 1 |
| Anwer, T | 1 |
| Phadnis, P | 1 |
| Dey Sarkar, P | 1 |
| Rajput, MS | 1 |
| Pereira, MM | 1 |
| de Morais, H | 2 |
| Dos Santos Silva, E | 1 |
| Corso, CR | 1 |
| Adami, ER | 1 |
| Carlos, RM | 1 |
| Acco, A | 1 |
| Zanoveli, JM | 2 |
| Contreras, CM | 1 |
| Gutiérrez-García, AG | 1 |
| Moreno-Cortés, ML | 1 |
| Nguyen, CM | 1 |
| Tartar, DM | 1 |
| Bagood, MD | 1 |
| So, M | 1 |
| Nguyen, AV | 1 |
| Gallegos, A | 1 |
| Fregoso, D | 1 |
| Serrano, J | 1 |
| Nguyen, D | 1 |
| Degovics, D | 1 |
| Adams, A | 1 |
| Harouni, B | 1 |
| Fuentes, JJ | 1 |
| Gareau, MG | 1 |
| Crawford, RW | 1 |
| Soulika, AM | 1 |
| Isseroff, RR | 1 |
| Gupta, D | 2 |
| Radhakrishnan, M | 2 |
| Kurhe, Y | 1 |
| El-Marasy, SA | 1 |
| Abdallah, HM | 1 |
| El-Shenawy, SM | 1 |
| El-Khatib, AS | 1 |
| El-Shabrawy, OA | 1 |
| Kenawy, SA | 1 |
| Habib, M | 1 |
| Shaker, S | 1 |
| El-Gayar, N | 1 |
| Aboul-Fotouh, S | 1 |
| Thangaraj, D | 1 |
| da Silva Dias, IC | 1 |
| Carabelli, B | 1 |
| Ishii, DK | 1 |
| de Carvalho, MC | 1 |
| Rizzo de Souza, LE | 1 |
| Zanata, SM | 1 |
| Brandão, ML | 1 |
| Cunha, TM | 1 |
| Ferraz, AC | 1 |
| Cunha, JM | 1 |
| Aswar, U | 1 |
| Chepurwar, S | 1 |
| Shintre, S | 1 |
| Aswar, M | 1 |
| Kamei, J | 1 |
| Miyata, S | 1 |
| Morita, K | 1 |
| Saitoh, A | 1 |
| Takeda, H | 1 |
| Anjaneyulu, M | 3 |
| Chopra, K | 3 |
| Kaur, I | 1 |
| Beauquis, J | 1 |
| Roig, P | 1 |
| Homo-Delarche, F | 1 |
| De Nicola, A | 1 |
| Saravia, F | 1 |
| Ramasamy, S | 1 |
| Hodgson, WC | 1 |
| Ventura, S | 1 |
| Kolta, MG | 1 |
| Soliman, KF | 1 |
| Williams, BB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of a Weight Management Program on Body Weight in Individuals Who Are Overweight and Otherwise Healthy[NCT04107155] | 54 participants (Actual) | Interventional | 2019-07-23 | Completed | |||
| A Randomized Controlled Trial to Evaluate the Effects of Repeated Periods of Modified Fasting to Support Healthy Natural Weight Management and Prevention of Weight Gain in Overweight But Generally Healthy Adults Over the Winter Holiday Period[NCT03372109] | 23 participants (Actual) | Interventional | 2017-11-14 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
22 other studies available for fluoxetine and Alloxan Diabetes
| Article | Year |
|---|---|
Oral fluoxetine treatment changes serotonergic sympatho-regulation in experimental type 1 diabetes.
Topics: Administration, Oral; Animals; Blood Pressure; Diabetes Mellitus, Experimental; Diabetes Mellitus, T | 2022 |
Fluoxetine Attenuated Anxiety-Like Behaviors in Streptozotocin-Induced Diabetic Mice by Mitigating the Inflammation.
Topics: Animals; Antidepressive Agents; Anxiety; Blotting, Western; Diabetes Mellitus, Experimental; Disease | 2019 |
Fluoxetine regulates glucose and lipid metabolism via the PI3K‑AKT signaling pathway in diabetic rats.
Topics: Animals; Cell Line; Chromones; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Fluoxetin | 2020 |
The antidepressant effect of melatonin and fluoxetine in diabetic rats is associated with a reduction of the oxidative stress in the prefrontal and hippocampal cortices.
Topics: Animals; Antidepressive Agents; Anxiety; Depression; Diabetes Mellitus, Experimental; Fluoxetine; Gl | 2017 |
Thymoquinone and fluoxetine alleviate depression via attenuating oxidative damage and inflammatory markers in type-2 diabetic rats.
Topics: Animals; Antioxidants; Behavior, Animal; Benzoquinones; Biomarkers; Cytokines; Depression; Diabetes | 2019 |
Improved serotonergic neurotransmission by genistein pretreatment regulates symptoms of obsessive-compulsive disorder in streptozotocin-induced diabetic mice.
Topics: Animals; Behavior, Animal; Brain; Diabetes Mellitus, Experimental; Disease Models, Animal; Fluoxetin | 2018 |
The antioxidant gallic acid induces anxiolytic-, but not antidepressant-like effect, in streptozotocin-induced diabetes.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Antioxidants; Anxiety; Behavior, Animal; Depres | 2018 |
Responsivity of lateral septum-mPFC connections in alloxan-induced hyperglycemia.
Topics: Alloxan; Animals; Antidepressive Agents; Brain; Diabetes Mellitus, Experimental; Fear; Fluoxetine; H | 2019 |
Topical Fluoxetine as a Novel Therapeutic That Improves Wound Healing in Diabetic Mice.
Topics: Animals; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetic Foot; Disease Models, Animal; Fe | 2019 |
Ondansetron, a 5HT3 receptor antagonist reverses depression and anxiety-like behavior in streptozotocin-induced diabetic mice: possible implication of serotonergic system.
Topics: Animals; Antidepressive Agents; Antiemetics; Anxiety; Behavior, Animal; Brain; Depression; Depressiv | 2014 |
Anti-depressant effect of hesperidin in diabetic rats.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Biogenic Monoamines; Brain-Derived Neurotrophic Fa | 2014 |
Anti-depressant effect of hesperidin in diabetic rats.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Biogenic Monoamines; Brain-Derived Neurotrophic Fa | 2014 |
Anti-depressant effect of hesperidin in diabetic rats.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Biogenic Monoamines; Brain-Derived Neurotrophic Fa | 2014 |
Anti-depressant effect of hesperidin in diabetic rats.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Biogenic Monoamines; Brain-Derived Neurotrophic Fa | 2014 |
The effects of antidepressants "fluoxetine and imipramine" on vascular abnormalities and Toll like receptor-4 expression in diabetic and non-diabetic rats exposed to chronic stress.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Blood Glucose; Blood Pressure; Blood Vessels; Body | 2015 |
A novel 5HT3 antagonist 4i (N-(3-chloro-2-methylphenyl)quinoxalin-2-carboxamide) prevents diabetes-induced depressive phenotypes in mice: Modulation of serotonergic system.
Topics: Animals; Antidepressive Agents; Biguanides; Brain; Depressive Disorder; Diabetes Mellitus, Experimen | 2016 |
Indoleamine-2,3-Dioxygenase/Kynurenine Pathway as a Potential Pharmacological Target to Treat Depression Associated with Diabetes.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Blood Glucose; Cytokines; Depression; Diabetes Mel | 2016 |
Telmisartan attenuates diabetes induced depression in rats.
Topics: Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Benzimidazoles; Benzoates; Brain; Depress | 2017 |
Effects of selective serotonin reuptake inhibitors on immobility time in the tail suspension test in streptozotocin-induced diabetic mice.
Topics: Adrenergic Uptake Inhibitors; Animals; Anti-Anxiety Agents; Blood Glucose; Body Weight; Desipramine; | 2003 |
Antidepressant activity of quercetin, a bioflavonoid, in streptozotocin-induced diabetic mice.
Topics: Animals; Antidepressive Agents; Depression; Diabetes Mellitus, Experimental; Disease Models, Animal; | 2003 |
Fluoxetine attenuates thermal hyperalgesia through 5-HT1/2 receptors in streptozotocin-induced diabetic mice.
Topics: Analgesics; Animals; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Fluoxetine; | 2004 |
Reduced hippocampal neurogenesis and number of hilar neurones in streptozotocin-induced diabetic mice: reversion by antidepressant treatment.
Topics: Animals; Antidepressive Agents, Second-Generation; Bromodeoxyuridine; Cell Count; Cell Proliferation | 2006 |
Possible involvement of cholinergic and opioid receptor mechanisms in fluoxetine mediated antinociception response in streptozotocin-induced diabetic mice.
Topics: Analgesics; Animals; Atropine; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Fl | 2006 |
Protein kinase C and the sub-sensitivity and sub-reactivity of the diabetic rat prostate gland to noradrenaline.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Atrop | 2002 |
Role of 5-hydroxytryptamine in the regulation of brain neuropeptides in normal and diabetic rat.
Topics: Animals; beta-Endorphin; Brain; Diabetes Mellitus, Experimental; Dopamine; Endorphins; Fenclonine; F | 1986 |